Company profile: Sonoma Bio
1.1 - Company Overview
Company description
- Provider of Treg and Teff cell therapies and autoimmune disease research, developing adoptive Treg therapies for rheumatoid arthritis, inflammatory bowel disease, and hidradenitis suppurativa. Pipeline includes SBT-77-7101, a Treg cell therapy targeting citrullinated proteins to reduce inflammation, and SBT-11-5301, a Phase 1 effector T cell-modulating biologic, with clinical trials assessing safety and effectiveness.
Products and services
- Treg and Teff Cell Therapies: Adoptive, immune-balancing products targeting regulatory and effector T cells to restore immune system balance in rheumatoid arthritis, inflammatory bowel disease, and hidradenitis suppurativa
- SBT-77-7101: Citrullinated protein-targeted, Treg cell therapy engineered to reduce inflammation by selectively addressing autoimmune drivers in rheumatoid arthritis and hidradenitis suppurativa
- SBT-11-5301: Phase 1, effector T cell-modulating biologic tested in healthy participants to assess safety while modulating effector T cells for autoimmune therapy development
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Sonoma Bio
Aeon Biopharma
HQ: United States
Website
- Description: Provider of biopharmaceutical therapies, developing novel and proprietary treatment paradigms to improve patient outcomes.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aeon Biopharma company profile →
Arvelle Therapeutics
HQ: Switzerland
Website
- Description: Provider of innovative biopharmaceutical solutions for patients suffering from central nervous system (CNS) disorders.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Arvelle Therapeutics company profile →
Nalu Medical
HQ: United States
Website
- Description: Provider of innovative medical technology solutions for patients with chronic neuropathic pain.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nalu Medical company profile →
Synaptive Medical
HQ: Canada
Website
- Description: Provider of neurosurgery, medical imaging and surgical navigation solutions, including the Synaptive Integrated Suite to integrate information and automation across interventions; Modus X robotic exoscope with 4K 3D and fluorescence visualization; Modus Plan automatic tractography segmentation; Modus Nav instrument tracking via intraoperative tractography; Synaptive MRI point-of-care MRI; ImageDrive zero-footprint HTML5 viewer.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Synaptive Medical company profile →
Onward
HQ: The Netherlands
Website
- Description: Provider of an implantable neuro-stimulation system (INS) with real-time motion feedback and training tools to rehabilitate patients with neurological disorders, including spinal cord injury (SCI).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Onward company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Sonoma Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Sonoma Bio
2.2 - Growth funds investing in similar companies to Sonoma Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Sonoma Bio
4.2 - Public trading comparable groups for Sonoma Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →